SOPHiA GENETICS and Jessa Ziekenhuis to Revolutionize Cancer Care through Precision Oncology Partnership

A New Dawn in Precision Oncology: SOPHiA GENETICS and Jessa Ziekenhuis

In a landmark development for cancer care in Belgium, SOPHiA GENETICS (Nasdaq: SOPH), a pioneering cloud-native healthcare technology firm, has unveiled its collaboration with Jessa Ziekenhuis, one of Belgium's largest hospitals. This strategic partnership was unveiled during the European Congress of Pathology and marks a significant step forward in precision oncology, aiming to enhance genomic testing and research in oncology for patients across Belgium.

Transforming Cancer Care with Cutting-Edge Technology

Jessa Ziekenhuis, which caters to over 530,000 residents and tests more than 3,000 oncology DNA and RNA samples each year, is set to implement SOPHiA DDM™. This innovative platform aims to unify their next-generation sequencing (NGS) workflows into a single, efficient system. By achieving standardization that encompasses universal library preparation and automated protocols, the hospital will not only enhance its operational efficiency but also ensure compliance with national guidelines set forth by ComPerMed.

The collaboration will see Jessa Ziekenhuis deploy a total of six tailored applications from SOPHiA GENETICS designed specifically for solid tumors, hematologic malignancies, and liquid biopsy analysis. This move is expected to significantly boost clinical decision-making capabilities along with research potential, opening new avenues for personalized treatment options.

Enhancing Workflow and Patient Care

The integration of SOPHiA GENETICS’ cloud-based platform will bring advanced automation and sophisticated analysis tools into Jessa's existing Laboratory Information Management System (LIMS). This streamlined approach is anticipated to reduce hands-on work time by an impressive 30–50%, shrink overall operational costs by up to 25%, and speed up testing turnaround times considerably. Furthermore, this comprehensive method promotes better utilization of sequencing technology while also allowing for effective tracking of implementation timelines and scalability.

One of the standout features of this collaboration is the SOPHiA DDM™ Dispatch, which allows Jessa Ziekenhuis to efficiently share a NovaSeq sequencer with AZ Delta hospital located in Roeselare, Belgium. This collaborative effort not only optimizes sequencing capabilities but also fosters knowledge sharing within the Bridge Consortium, further enhancing service provision across their respective facilities.

Commitment to Innovation and Patient Care

Dr. Brigitte Maes, a Clinical Pathologist at Jessa Ziekenhuis, expressed excitement about the partnership, emphasizing the hospital's commitment to innovation and advanced oncological care. With this collaboration in place, the hospital aims to generate faster and more precise molecular insights, which will directly enhance patient care and improve clinical outcomes in oncology.

Kevin Puylaert, Managing Director of EMEA at SOPHiA GENETICS, echoed this sentiment, stating that their partnership with Jessa Ziekenhuis illustrates their capacity to support leading institutions in bolstering their genomic capabilities. He highlighted that by providing a fully automated cloud-native solution custom-made for oncology, they are empowering the hospital to streamline workflows and elevate patient care across Belgium.

Through this collaboration, SOPHiA GENETICS reinforces its reach within European hospital networks, aiming to facilitate scalable, data-driven precision medicine initiatives. As the healthcare landscape continues to evolve towards personalized treatments, strategic partnerships like this one are crucial for improving patient outcomes in cancer care.

For those interested in learning more about SOPHiA GENETICS and their innovations in the field of genomics and personalized medicine, further information can be found on their website or through various professional networking platforms.

Conclusion

The partnership between SOPHiA GENETICS and Jessa Ziekenhuis is set to redefine the approach towards cancer diagnostics and treatment in Belgium. By merging advanced genomic technology with practical applications in healthcare, this collaboration is poised to make significant contributions to oncology, placing patient care at its core.